ASCO 2026 was the most consequential oncology meeting in years. The plenary sessions set three new treatment standards in a single afternoon—Revolution’s daraxonrasib in pancreatic cancer, Akeso’s ivonescimab in lung cancer, J&J’s Erleada in perioperative prostate cancer. We covered those in detail yesterday. But the oral abstract sessions were nearly as important. The KEYNOTE-B15/EV-304 data in bladder cancer showed that combining an ADC with a checkpoint inhibitor before and after surgery produced pathologic complete responses in more than half of patients—55.8% versus 32.5% for chemotherapy (p<0.0001). Kelonia’s in vivo CAR-T presentation gave the first detailed look at the data that led Lilly to pay $3.2 billion for the company. Fierce Biotech said the data helped “justify” the price tag. J&J’s CHRYSALIS-2 update showed 41-month median OS with Rybrevant plus Lazcluze in atypical EGFR NSCLC. Hengrui presented more than 90 studies. Outside ASCO, Apogee locked in $1.3 billion from Blackstone for atopic dermatitis development. And the next conference is already on deck: ADA 2026 with GLP-1 obesity data as the headliner.
See the full searchable ASCO 2026 agenda — every Plenary readout, filterable by tumor track → biomednexus.com/asco-2026
ASCO Wrap-Up: The Data That Mattered Beyond the Plenary
Bladder Cancer: ADC Plus IO Combination Produces 55.8% Complete Response
What Happened: The Phase 3 KEYNOTE-B15/EV-304 trial showed that enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) produced a 55.8% pathologic complete response rate in perioperative muscle-invasive bladder cancer, compared with 32.5% for gemcitabine/cisplatin chemotherapy (estimated difference 23.4%, p<0.0001).
Why This Matters: This is the ADC-plus-checkpoint-inhibitor combination thesis validated in yet another tumor type. The pattern has been building throughout 2026. Merck’s sac-TMT plus Keytruda cut progression risk by 65% in first-line lung cancer (OptiTROP-Lung05 abstract). Now Padcev plus Keytruda has produced a pathologic complete response rate that nearly doubles chemotherapy in perioperative bladder cancer. In both cases, the combination of an ADC (which delivers cytotoxic payload directly to tumor cells) with a checkpoint inhibitor (which unleashes the immune system against cancer) produces results that neither modality achieves alone.
A pathologic complete response means no cancer is found in the surgical specimen after treatment. In the perioperative setting, this is the strongest possible indicator that the disease has been eliminated. A 55.8% pCR rate in bladder cancer—a disease where chemotherapy has been the perioperative standard for decades—is a practice-changing result that will prompt regulatory submissions and rewrite treatment guidelines.
The result also reinforces the broader perioperative movement that defined ASCO 2026. Enhertu in early breast cancer. Datroway in first-line TNBC. Erleada in perioperative prostate cancer. And now Padcev plus Keytruda in perioperative bladder cancer. Across tumor types, the direction is consistent: oncology treatments are moving earlier in the disease course, where the intent shifts from palliation to cure and patient populations are larger.
Kelonia In Vivo CAR-T Data Justify Lilly’s $3.2B Investment
What Happened: Fierce Biotech reported that Kelonia “shared the largest slice of data yet for its in vivo CAR-T, helping to justify the $3.2 billion price tag Lilly recently paid for the biotech.” The data from the KLN-1010 program (lentiviral in vivo anti-BCMA CAR-T for multiple myeloma) were presented at ASCO.
Why This Matters: Lilly paid up to $7 billion for Kelonia (including $3.25 billion upfront) based on preclinical data and the promise of a platform that could deliver CAR-T therapy without the complex, costly ex vivo manufacturing process that current CAR-T products require. Today’s standard CAR-T therapies (Yescarta, Carvykti, Abecma) require extracting a patient’s T-cells, engineering them in a manufacturing facility, and re-infusing them—a process that takes weeks, costs hundreds of thousands of dollars, and limits access to specialized treatment centers.
In vivo CAR-T eliminates the manufacturing step entirely by engineering the patient’s own T-cells inside the body using a viral or non-viral delivery vehicle. If the approach works at scale, it could make cell therapy as accessible as an injection—administered in any oncology clinic rather than restricted to academic medical centers with apheresis capabilities.
The ASCO presentation gave the oncology community its first detailed look at the clinical evidence behind Lilly’s investment. Fierce Biotech’s assessment that the data “justified” the price tag signals that the early clinical results support the platform thesis. The full implications for Lilly’s cell therapy strategy—spanning Kelonia (lentiviral in vivo CAR-T for myeloma) and Orna (circular RNA in vivo CAR-T for autoimmune disease)—will become clearer as the programs advance through clinical development.
J&J Rybrevant Plus Lazcluze: 41-Month OS in Atypical EGFR NSCLC
What Happened: Updated CHRYSALIS-2 data showed amivantamab (Rybrevant) plus lazertinib (Lazcluze) achieved a median OS of 41.0 months at 31.3 months of follow-up in first-line atypical EGFR-mutated advanced NSCLC. 55% of patients were alive at three years.
Why This Matters: Atypical EGFR mutations are a subset of NSCLC that has historically been poorly served by standard EGFR-targeted therapies designed for the more common classical mutations (exon 19 deletion, L858R). These atypical mutations—which include exon 20 insertions and other uncommon variants—do not respond well to first-generation or second-generation EGFR tyrosine kinase inhibitors. Patients with atypical mutations have had limited treatment options and substantially worse outcomes compared to patients with classical mutations.
A median OS of 41 months in this population represents a transformative improvement over historical benchmarks, where survival was typically measured in the teens of months. Fifty-five percent of patients alive at three years is a landmark for a population that has historically faced a grim prognosis. Investigators noted the regimen has demonstrated “substantial survival benefit in both classical and atypical EGFR-mutated advanced NSCLC,” solidifying J&J’s lung cancer franchise across the full spectrum of EGFR-driven disease.
The Rybrevant plus Lazcluze combination is distinctive because amivantamab is a bispecific antibody targeting both EGFR and MET, while lazertinib is a third-generation EGFR TKI. The dual-targeting approach addresses resistance mechanisms that limit single-agent EGFR therapy—when tumors develop resistance to one pathway, the other pathway continues to suppress growth. This mechanistic breadth may explain the exceptional survival duration observed in the atypical population.
Hengrui Presented 90+ Studies
Hengrui Pharmaceuticals presented more than 90 oncology studies at ASCO 2026, the largest ASCO presence by any Chinese pharmaceutical company and one of the largest by any company in the world. The data spanned multiple tumor types and modalities including small molecules, antibodies, ADCs, and combination regimens, reinforcing Hengrui’s position as a leading source of clinical-stage oncology assets for Western licensing partners.
The scale of Hengrui’s presence matters because it demonstrates the depth of the pipeline behind the licensing headlines. BMS signed a $15.2 billion deal with Hengrui in May covering 13 programs. Lilly partnered via Kailera. These deals were based on the quality of individual assets. The 90-plus ASCO studies show that the pipeline behind those assets is deep and productive—suggesting that Hengrui’s current licensing deals represent the beginning, not the end, of the company’s contribution to Western pharma pipelines.
The contrast with even five years ago is stark. Chinese pharmaceutical companies presenting single-digit studies at ASCO was the norm. Ninety-plus studies from a single company signals that China’s investment in oncology R&D has matured from early-stage exploration to industrial-scale clinical development.
Apogee Locks In $1.3B from Blackstone for Atopic Dermatitis
What Happened: Apogee Therapeutics entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive capital to support development and potential commercialization of zumilokibart in atopic dermatitis.
Why This Is One of the Largest Biotech Financings of the Year
Zumilokibart is an anti-OX40L antibody in Phase 2/3 development for atopic dermatitis, a chronic inflammatory skin condition that affects millions of patients and represents a multi-billion-dollar market dominated by AbbVie’s Dupixent franchise and the emerging JAK inhibitor class.
The Blackstone financing is notable for its structure and scale. At up to $1.3 billion, it is one of the largest non-dilutive biotech financings of 2026. Non-dilutive financing means Apogee does not issue new shares to raise the capital, preserving existing shareholders’ ownership stakes while providing a runway to complete pivotal development and potentially build commercial infrastructure. For Blackstone, the deal provides exposure to a clinical-stage immunology asset with blockbuster potential through a structured return rather than equity ownership.
The atopic dermatitis market is large and growing. Dupixent (dupilumab) has proven that biologic therapy can transform outcomes for moderate-to-severe AD patients, generating billions in annual revenue and establishing the category. The OX40L mechanism that zumilokibart targets is differentiated from both the IL-4/IL-13 pathway (Dupixent) and the JAK pathway (Rinvoq, Cibinqo), potentially providing a treatment option for patients who do not respond adequately to existing therapies or who prefer a different mechanism of action.
The non-dilutive financing structure is increasingly attractive for clinical-stage biotechs that need substantial capital to complete pivotal programs but want to avoid the share dilution that traditional equity raises create. Blackstone Life Sciences has been one of the most active providers of this type of financing in 2026, deploying capital across multiple biotech companies through structures that provide returns tied to product milestones and commercial performance rather than equity appreciation. For Apogee, the $1.3 billion commitment provides the financial runway to complete Phase 3 development, prepare regulatory submissions, and potentially build the commercial infrastructure needed for launch—all without issuing new shares.
ASCO 2026: The Five Themes That Define the Next 12 Months
Looking back at the full conference, five themes emerged that will shape oncology dealmaking, drug development, and clinical practice through the rest of 2026 and into 2027:
ADCs moved from late-line to frontline and curative settings. Enhertu in early breast cancer. Datroway in first-line TNBC. Padcev plus Keytruda in perioperative bladder cancer. sac-TMT plus Keytruda in first-line lung cancer. The modality is no longer a salvage therapy—it is becoming a foundational treatment across multiple tumor types and treatment settings.
RAS inhibitors emerged as a new pillar of GI oncology. Daraxonrasib’s OS HR of 0.40 in second-line pancreatic cancer established the first targeted therapy with a survival benefit in PDAC. Revolution’s CNPV filing is imminent. The company has first-line combination data and next-generation candidates in the pipeline.
Bispecific antibodies produced their first OS data. Ivonescimab demonstrated that a PD-1/VEGF bispecific can improve overall survival over PD-1 alone—the first time any bispecific has shown this in a Phase 3 trial.
In vivo CAR-T moved from preclinical to clinical validation. Kelonia’s ASCO presentation gave the oncology community its first detailed clinical evidence for a technology that could make cell therapy accessible far beyond academic medical centers.
China’s oncology pipeline went mainstream. Hengrui presented 90-plus studies. Akeso got the first Chinese plenary in 61 years. Kelun-Biotech’s sac-TMT produced two Phase 3 wins for Merck. The data quality from Chinese biotech is now undeniable, even as the political pressure to restrict China-West collaboration intensifies.
Our Pro brief analyzes these five themes in depth, assesses which ASCO datasets are most likely to drive M&A activity in the coming months, and maps the regulatory filing timelines for the key ASCO programs. [Details below.]
Strategic Themes
1. The ADC-Plus-IO Combination Is Now Validated Across Four Tumor Types
Lung cancer (sac-TMT plus Keytruda, 65% PFS reduction). Bladder cancer (Padcev plus Keytruda, 55.8% pCR). The combination of ADC cytotoxicity and checkpoint inhibitor immune activation is producing consistently superior results across tumor types and treatment settings. This is no longer an experimental approach—it is becoming a new treatment paradigm that will generate regulatory filings and treatment guideline revisions across oncology over the next 12 months.
2. ASCO Produced the Data That Will Drive the Next Wave of M&A
Practice-changing datasets create acquisition targets and partnership opportunities. Revolution’s daraxonrasib data will accelerate the KRAS competitive landscape. The ADC combination data will drive further investment in the modality. Ivonescimab’s OS data will attract global partnership interest for Summit and Akeso. With biopharma M&A running at approximately $93 billion through April and deal pace showing no signs of slowing, the ASCO data cycle will catalyze the next wave of transactions.
3. The Transition from Conference to Commerce Begins Now
ASCO is over. The filings start. Revolution’s CNPV NDA is imminent. Merck’s sac-TMT global filing (TroFuse-007) is expected in H2. J&J will pursue the Erleada perioperative indication. Padcev plus Keytruda will seek a bladder cancer submission. The data have been presented. The peer review is done (NEJM for daraxonrasib). The regulatory interactions begin. The next 90 days will determine which of these programs reaches patients first.
4. ADA Is Next—and the Obesity Story Is Far from Over
The American Diabetes Association annual congress is up next with GLP-1 obesity data as the headliner. BioSpace framed it as “obesity Davids and Goliaths face off at ADA 2026.” With retatrutide’s 28.3% weight-loss data fresh, Foundayo’s launch still ramping, Novo’s oral Wegovy commanding 65% of new obesity prescriptions, and multiple new entrants including Boehringer Ingelheim/Zealand Pharma’s dual-acting shot approaching the market, the competitive dynamics in obesity are evolving faster than any other therapeutic area. ADA will provide the next dataset inflection. The Jefferies Global Healthcare Conference opens June 4 in New York, where management teams will provide post-ASCO strategic commentary and address how the conference data reshape their pipeline and M&A priorities. The overlap of ADA obesity data and Jefferies management presentations creates a dense week of information for investors and industry observers.
Frequently Asked Questions
What were the key non-plenary ASCO results?
EV-304: 55.8% pathologic complete response with Padcev plus Keytruda in perioperative bladder cancer (vs 32.5% chemo). Kelonia in vivo CAR-T data that Fierce Biotech said “justified” Lilly’s $3.2B acquisition. CHRYSALIS-2: 41-month median OS with Rybrevant plus Lazcluze in atypical EGFR NSCLC. Hengrui presented 90+ oncology studies.
What is the EV-304 bladder cancer result?
Padcev (enfortumab vedotin) plus Keytruda produced 55.8% pathologic complete response versus 32.5% for chemotherapy in perioperative muscle-invasive bladder cancer (p<0.0001). This validates the ADC-plus-checkpoint-inhibitor combination in bladder cancer and positions the regimen as a potential new perioperative standard.
What did Kelonia show at ASCO?
The first detailed clinical data for its KLN-1010 lentiviral in vivo anti-BCMA CAR-T program for multiple myeloma. Fierce Biotech said the data helped “justify the $3.2 billion price tag Lilly recently paid.” In vivo CAR-T eliminates the ex vivo manufacturing step that limits current cell therapy access and cost.
What is the Apogee/Blackstone deal?
Up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences to support development and commercialization of zumilokibart (anti-OX40L antibody) in atopic dermatitis. One of the largest non-dilutive biotech financings of 2026.
What conference is next?
ADA 2026 (American Diabetes Association) with GLP-1 obesity data. Jefferies Global Healthcare Conference opens June 4 in New York.
When is the Medicare GLP-1 Bridge launching?
July 1. Four weeks out. The program provides GLP-1 access for Medicare Part D beneficiaries at $50 per month copay.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
ASCO 2026 in Review. We analyze the five themes that will define oncology dealmaking, drug development, and clinical practice for the next 12 months—and assess which datasets are most likely to trigger M&A discussions, regulatory submissions, and treatment guideline revisions in the months ahead.
ADC Plus IO: The Combination Thesis Is Complete. We assess how the EV-304 bladder data join the sac-TMT lung data, the Enhertu breast data, and the Datroway TNBC data to establish ADC-plus-checkpoint-inhibitor as a validated treatment paradigm across oncology, and identify which tumor types are next.
China at ASCO. We analyze what 90-plus Hengrui studies, the first Chinese plenary in 61 years, and Kelun-Biotech’s two Phase 3 wins mean for the China-West licensing pipeline—and how the COINS Act debate intersects with data quality that the global oncology community can no longer dismiss.
Plus: Apogee/Blackstone financing analysis, Kelonia in vivo CAR-T commercial implications, ADA preview, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
